RAPGEF1 and metabolic dysfunction-associated steatohepatitis: Hence, the analysis of data from public databases indicate that RapGEF1 mRNA expression decreased in liver samples from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) patients compared to healthy livers (Supplementary Fig. 4B).